Search Grant Opportunities

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)

ID: PAR-21-137 • Type: Posted
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Sign in to upload a capability statement or catalogue for your company

Popular Questions:
Generate a draft:
Loading

Description

This is a reissue of RFA-MH-18-702: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33- Clinical Trial Required). NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this FOA encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.

Overview

Category of Funding
Health
Funding Instruments
Grant
Grant Category
Discretionary
Cost Sharing / Matching Requirement
False
Source
On 3/2/21 the National Institutes of Health posted grant opportunity PAR-21-137 for Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required). The grant will be issued under grant program 93.242 Mental Health Research Grants.

Timing

Posted Date
March 2, 2021, 12:00 a.m. EST
Closing Date
Oct. 15, 2024, 12:00 a.m. EDT Past Due
Last Updated
Jan. 17, 2024, 11:25 a.m. EST
Version
2
Archive Date
Nov. 14, 2024

Eligibility

Eligible Applicants
Independent school districts
County governments
Public and State controlled institutions of higher education
City or township governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
For profit organizations other than small businesses
State governments
Native American tribal organizations (other than Federally recognized tribal governments)
Private institutions of higher education
Special district governments
Public housing authorities/Indian housing authorities
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Native American tribal governments (Federally recognized)
Small businesses
Additional Info
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Contacts

Contact
National Institutes of Health
Contact Email
Email Description
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Contact Phone
(301) 402-2541

Documents

Posted documents for PAR-21-137

Opportunity Assistant


AI Analysis

AI Generate

Grant Awards

Grants awarded through PAR-21-137

Incumbent or Similar Grants

Similar Active Opportunities

Open grant opportunities similar to PAR-21-137

Experts for Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)

Recommended subject matter experts available for hire